L929/R

Development of novel anti-cancer treatments

Mouse C3H/An connective tissue cisplatin resistant

This cisplatin-resistant cell line has been developed by exposure of the parent L929 murine fibroblast cell line (Sigma Catalogue number. 85011425) to increasing concentrations of cisplatin in vitro. L929/R cells can be used in the development of novel anti-cancer treatments. The parent cell line L929 was derived from normal subcutaneous areolar adipose tissue.

RPMI 1640 + 2mM L-Glutamine + 10% Foetal Bovine Serum (FBS) + 0.26μM Cisplatin.

Split sub-confluent cultures (70-80%) 1:5 to 1:50 i.e. seeding at 1-2x10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 2% CO₂; 37 C.

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.